Myriad Genetics (MYGN) Depreciation and Depletion (2014 - 2026)

Myriad Genetics (MYGN) has reported Depreciation and Depletion for 13 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation and Depletion fell 7.84% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $19.1 million (down 2.05% YoY), while the FY2025 annual figure was $19.5 million, changed 0.0% from the prior year.
• Depreciation and Depletion steadied at $4.7 million in Q1 2026 per MYGN's latest filing, from $4.7 million in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $8.7 million in Q1 2023 and bottomed at $2.7 million in Q2 2023.
• Historically, Depreciation and Depletion has averaged $4.4 million across 5 years, with a median of $4.7 million in 2025.
• Annual changes were most pronounced in 2023 — Depreciation and Depletion jumped 210.71% — and 2024, when it tumbled 43.68%.
• Myriad Genetics' Depreciation and Depletion stood at $3.1 million in 2022, then soared by 38.71% to $4.3 million in 2023, then climbed by 16.28% to $5.0 million in 2024, then decreased by 6.0% to $4.7 million in 2025, then changed by 0.0% to $4.7 million in 2026.
• Business Quant data shows MYGN's Depreciation and Depletion at $4.7 million in Q1 2026, $4.7 million in Q4 2025, and $4.8 million in Q3 2025.